SynthesisMedicine2019

Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: A meta-analysis.

Danping Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.